相关实验视频

Updated: Jul 10, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

肺腺癌的临床,基因组和转录组特征与不常见的EGFR突变

Kazuki Hayasaka¹, Haruna Takeda², Akira Sakurada³

¹Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan; Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.

Clinical lung cancer

|November 20, 2023

概括

在肺腺癌患者中不常见的EGFR突变表明预后较差和独特的基因组特征. 这些瘤可能会更好地响应免疫疗法,因为它们具有不同的转录基因特征.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
翻译研究是翻译研究.

背景情况:

肺腺癌 (LUAD) 是癌症相关死亡的主要原因.
表皮生长因子受体 (EGFR) 突变是LUAD的关键驱动因素.
区分常见 (CM) 和不常见 (UCM) 的EGFR突变对于治疗策略至关重要.

研究的目的:

为了比较UCM与CM的LUAD患者的临床,基因组和转录组特征.
评估UCM在手术切除的LUAD中的预后影响.

主要方法:

对466名患有EGFR突变的LUAD患者的回顾性分析.
评估整体存活率 (OS) 和无复发存活率 (RFS).
使用公共数据库进行基因组和转录组分析.

主要成果:

在10.9%的患者中发现UCM;与显著更短的OS和RFS相关 (P < .01).
UCM是OS (HR 1.72) 的一个独立的负预后因素.
UCM瘤呈现较高的瘤突变负担,TP53突变和T细胞炎症基因特征.

结论:

不常见的EGFR突变预示着可切除的LUAD的预后较差.
UCM瘤具有不同的基因组和转录组特征.
这些特征表明,在UCM驱动的LUAD中,免疫治疗反应的可能性很大.

关键词:

基因组基因组基因组基因组基因组肺部腺癌瘤是肺部腺癌.外科手术手术手术转录组转录组就是一个转录组.不常见的EGFR突变

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...